Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.
Journal: Advances in therapy
Published: March 17, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026
VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.
Journal: Breast cancer research and treatment
Published: March 10, 2026
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.
Journal: Breast (Edinburgh, Scotland)
Published: November 11, 2025
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Journal: The New England journal of medicine
Published: October 29, 2025
Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.
Journal: Clinical pharmacology and therapeutics
Published: September 17, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Journal: Journal of the National Cancer Institute
Published: June 30, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Journal: JCO precision oncology
Published: April 03, 2025
HER2-Positive Breast Cancer Treatment and Resistance.
Journal: Advances in experimental medicine and biology
Published: January 17, 2025
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.
Journal: bioRxiv : the preprint server for biology
Published: December 23, 2024
Last Updated: 09/26/2026